Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Significant Decrease in Short Interest

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 10,600 shares, a decrease of 85.7% from the February 29th total of 74,000 shares. Based on an average daily volume of 1,520,000 shares, the days-to-cover ratio is presently 0.0 days.

Provectus Biopharmaceuticals Trading Down 8.5 %

Provectus Biopharmaceuticals stock traded down $0.02 during midday trading on Thursday, hitting $0.18. The stock had a trading volume of 236,436 shares, compared to its average volume of 313,251. The firm’s fifty day moving average is $0.15 and its two-hundred day moving average is $0.12. Provectus Biopharmaceuticals has a 52-week low of $0.06 and a 52-week high of $0.22.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis.